<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03508661</url>
  </required_header>
  <id_info>
    <org_study_id>17-112</org_study_id>
    <nct_id>NCT03508661</nct_id>
  </id_info>
  <brief_title>The Scleroderma Patient-centered Intervention Network (SPIN) Support Group Leader Education Program Feasibility Trial</brief_title>
  <acronym>SPIN-SSLED-F</acronym>
  <official_title>The Scleroderma Patient-centered Intervention Network (SPIN) - Scleroderma Support Group Leader EDucation (SSLED) Program Feasibility Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lady Davis Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lady Davis Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many people living with a rare disease turn to peer-led support groups to cope with their
      condition and access educational resources. Systemic sclerosis (SSc), or scleroderma, is a
      rare autoimmune connective tissue disease where peer-led support groups play an important
      role. There are currently approximately 200 SSc support groups in Canada and the US, most of
      which are led by people with SSc. Many SSc patients, however, cannot access support groups.
      In other cases, support groups are not sustained due to factors that include the burden on
      group leaders living with a serious, unpredictable disease and limited group leadership
      skills of some untrained leaders. Our partners from Scleroderma Canada and the Scleroderma
      Foundation in the US are committed to improving support group accessibility and
      effectiveness. These organizations maintain a list of active support groups, but currently do
      not provide training or other resources to groups or their leaders. To address this gap, our
      team, including investigators and patients from the Scleroderma Patient-centered Intervention
      Network (SPIN), developed the Scleroderma Support group Leader EDucation (SPIN-SSLED)
      Program, which is designed to improve support group leader confidence and self-efficacy,
      reduce burnout, improve emotional well-being, and improve health-related quality of life.

      In the planned full-scale randomized controlled trial (RCT) that will follow our feasibility
      trial, we will evaluate whether the SPIN-SSLED Program is effective in improving SSc support
      group leaders' self-efficacy for carrying out their leader role (primary) and if it reduces
      burnout, improves emotional well-being, and improves health-related quality of life
      (secondary). Thus, the SPIN-SSLED Feasibility Trial answers the following research questions:
      (1) Is a full-scale SPIN-SSLED RCT feasible? (2) Are adaptations needed to the research
      design for the planned full-scale RCT? (3) Are there ways to improve the SPIN-SSLED Program
      for delivery in the planned full-scale RCT based on input of support group leaders who
      participate in the feasibility trial?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People with rare diseases experience many of the same challenges as those with more common
      diseases, but also face unique challenges, including gaps in knowledge about their disease
      and limited treatment and support options. Professionally organized support services are
      often available for people with more common diseases but are not typically available for
      people with rare diseases. Instead, many people with rare diseases rely on peer-led support
      groups for education and to cope with their disease. Support groups may be held face-to-face
      or online, led by professionals or peers, and have a structured or an unstructured format.
      Activities typically involve an educational or information-sharing component and the exchange
      of emotional and practical support.

      SSc is a rare, chronic, autoimmune connective tissue disease characterized by abnormal
      fibrotic processes and excessive collagen production. Peer-led support groups play an
      important role for people with the disease. There are currently approximately 200 active SSc
      support groups listed by Scleroderma Canada or the Scleroderma Foundation in the USA, most
      led by people with the disease. Many people with SSc, however, do not have access to SSc
      support groups, and many support groups that are initiated are not sustained due to obstacles
      that could be addressed by providing training to support group leaders. Challenges for
      patient support group leaders, particularly in rare diseases, include practical difficulties,
      such as a lack of resources or poor coordination with medical professionals and leader
      organizations; difficulties with group leadership tasks, such as managing complex group
      dynamics; and personal challenges, such as managing one's own health condition while
      supporting others and preventing burnout.

      A training and education program could provide the necessary information and skills to
      improve the ability of SSc peer support group leaders to lead sustainable, effective support
      groups; reduce their emotional and physical burden; and encourage new leaders to set up
      support groups where none exist or via the internet. In rare diseases, face-to-face delivery
      of such a training program is not feasible because current and potential leaders are widely
      dispersed geographically. Videoconferencing has been used successfully to train educators,
      health service providers, and parents of children with behavioural difficulties, for example,
      and is as effective as face-to-face training.

      The SPIN-SSLED Program was developed by a team of researchers with expertise in SSc, patient
      organization representatives, and a Patient Advisory Board comprised of current SSc support
      group leaders. The program content and design are based on results of our preliminary
      research on support groups in SSc and informed by instructional material for support group
      leaders we identified via the internet and by consultations with support group leaders. The
      program uses a problem-based learning approach. Problem-based learning is a learner-centered
      approach that integrates theory and practice by providing the necessary knowledge and skills,
      presenting a complex, real-world problem, then working to identify an approach to solving the
      problem. To implement this, each module, or learning session, will introduce a topic and
      provide an overview of key information. Then, there will be a guided discussion among
      training group participants about possible approaches and solutions. The program includes 13
      modules that will be delivered live via webinar over the course of the 3-month program. In
      addition to the live modules, SPIN-SSLED participants will receive a workbook that summarizes
      didactic material that is provided and will be shown filmed vignettes demonstrating effective
      group facilitation techniques and ways to respond to support group issues. SPIN-SSLED
      participants will also have access to an online resource center that includes a range of
      helpful tools for leaders including files of SSc related videos to show at meetings and an
      online forum for leaders to post questions, open only to leaders enrolled in the training
      program.

      The proposed SPIN-SSLED Program Feasibility Trial builds on this background research and will
      evaluate the feasibility of delivering the SPIN-SSLED Program and of our planned full-scale
      trial design. The objectives of this study are (1) To evaluate the feasibility of steps
      needed to take place in the full-scale trial, including the required resources (e.g.,
      staffing, time, and budget), management issues (e.g., related to optimizing performance of
      personnel and data systems), and scientific aspects (e.g., recruitment of eligible leaders,
      fidelity of intervention delivery, acceptability of intervention to leaders, assessing
      performance of outcome measures); (2) To make any necessary modifications to the SPIN-SSLED
      Program based on participant feedback

      The aim of the SPIN-SSLED Feasibility Trial is to collect data related to the study's
      process, in order to assess the feasibility of the steps that need to take place as part of
      the main study; required resources (e.g., staffing, time, and budget), management issues
      (e.g., optimizing performance of personnel and data systems); and scientific aspects (e.g.,
      recruitment rates of eligible leaders, fidelity of intervention delivery, acceptability of
      intervention to leaders, performance of outcome measures).

      Our partners from the Scleroderma Canada and the Scleroderma Foundation will contact group
      leaders to describe the SPIN-SSLED Feasibility Trial and ascertain interest in participating.
      SPIN-SSLED personnel will send email invitations with the consent form to interested support
      group leaders. Following this, support group leaders will be contacted by phone within 48
      hours to describe the study, review the consent form, and answer questions assessing
      eligibility. Eligible patients who verbally accept the offer to enrol in the study will
      receive an email with the consent form for the study, which they can sign by replying, &quot;I
      have read the consent form and understand the terms of the feasibility study. I agree to
      participate in the study testing the feasibility of the SPIN-SSLED Program.&quot; We will enroll
      10 SSc support group leaders to participate in the program. Based on our previous experience
      with videoconferencing and consistent with previous trials of videoconference training, to
      maximize effective interaction and participation, 5 group leaders will be assigned to each
      training group. Training sessions will be delivered using the GoToMeetingÂ® videoconferencing
      platform, a high-performance platform that has been used successfully for similar
      applications.

      A survey will be administered to all participants before the trial. The survey will contain a
      demographics questionnaire designed for this study that includes basic demographic
      information, such as gender, age and employment status. The survey also includes
      disease-related variables, such as years since scleroderma diagnosis and questionnaires for
      all outcome measures. These questionnaires will be administered again upon completion of the
      program, along with a satisfaction questionnaire. All questionnaires will be completed using
      the online surveying tool Qualtrics. Once the online survey data is collected, data will be
      exported to the statistics software program, IBM SPSS.

      A description of feasibility outcomes will be presented, including leader eligibility and
      recruitment, leader enrolment and randomization, technological performance of the
      videoconferencing system, and treatment fidelity. Qualitative information will inform any
      necessary changes to the program or trial methods before conducting a full-scale trial.
      Descriptive statistics will be used to provide means and standard deviations for SPIN-SSLED
      Program outcome measures.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 18, 2018</start_date>
  <completion_date type="Anticipated">July 19, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 19, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant feedback on usability of program materials</measure>
    <time_frame>13 weeks</time_frame>
    <description>Participant interviews</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant feedback on ease of use of the GoTo videoconferencing program</measure>
    <time_frame>13 weeks</time_frame>
    <description>Participant interviews</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant feedback on ease of use of the online forum</measure>
    <time_frame>13 weeks</time_frame>
    <description>Participant interviews</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Personnel requirements</measure>
    <time_frame>13 weeks</time_frame>
    <description>Time logs completed by research staff will be used to assess personnel requirements for the full-scale trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Challenges for study personnel</measure>
    <time_frame>13 weeks</time_frame>
    <description>Trainer interviews on challenges in training format, group management, and logistical aspects of the program</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fidelity to program manual</measure>
    <time_frame>13 weeks</time_frame>
    <description>Intervention fidelity will be evaluated through the observation of entire sessions for a randomly selected sample of 25% of video-recorded sessions. Raters will evaluate adherence to each session's goals and content using a checklist coding system based on a standardized format</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Technological performance of the GoTo videoconferencing platform</measure>
    <time_frame>13 weeks</time_frame>
    <description>Log of technological problems reported by staff and participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Scleroderma Support Group Leader Self-efficacy Scale (SSGLSS)</measure>
    <time_frame>13 weeks</time_frame>
    <description>The SSGLSS consists of 32 core items that assess the confidence of SSc support group leaders to carry out tasks necessary for leading a support group successfully. Items are scored on a 6-point scale ranging from Strongly Disagree to Strongly Agree (scored 0-5). Possible total scores range from 0 to 160 with higher scores indicating greater self-efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal Health Questionnaire (PHQ-8)</measure>
    <time_frame>13 weeks</time_frame>
    <description>The PHQ-8 is a self-administered 8-item scale to assess depression that has been validated for use in populations with SSc. Items are rated on a 4-point Likert scale (not at all, several days, more than half the days, nearly every day) with higher scores indicating higher levels of depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes Measurement Information System (PROMIS-29) profile version 2.0</measure>
    <time_frame>13 weeks</time_frame>
    <description>The PROMIS-29 measure contains 29 items, which include four items each for domains reflecting physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and ability to perform social roles, plus a single item on pain intensity. Higher scores represent more of the domain being measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oldenburg Burnout Inventory (OLBI).</measure>
    <time_frame>13 weeks</time_frame>
    <description>The OLBI is a 16-item measure of burnout that assesses levels of exhaustion and disengagement in work populations. Items were adapted and reviewed by project investigators for use within the support group leader population. Items are scored on a 4-point scale from 1 (strongly disagree) to 4 (strongly agree)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Scleroderma</condition>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>SPIN-SSLED Program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SPIN-SSLED Program</intervention_name>
    <description>The program includes 13 modules that will be delivered live via webinar over the course of the 3-month program. Each module will be delivered in a 60- to 90-minute session. Module topics include (1) the leader's role; (2) starting a support group; (3) structuring a support group meeting; (4) scleroderma 101; (5) successful support group culture; (6 &amp;7) managing support group dynamics I and II; (8) grief and crisis in scleroderma; (9) marketing and recruitment; (10) the continuity of the group; (11) supporting yourself as a leader; (12) virtual support group meetings, (13) support group leader resources. Participants will receive a workbook, be shown filmed vignettes, and will have access to an online resource center.</description>
    <arm_group_label>SPIN-SSLED Program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be a current SSc support group leader or have been identified by Scleroderma Canada or
             the Scleroderma Foundation as a new leader who will initiate a new support group

          -  Be available to participate at times when sessions are scheduled

          -  Be English-speaking

        Exclusion Criteria:

          -  Unable to use the internet to access and participate in training sessions or to
             complete study questionnaires online
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3S 1Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2018</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lady Davis Institute</investigator_affiliation>
    <investigator_full_name>Brett Thombs</investigator_full_name>
    <investigator_title>Professor, Faculty of Medicine, McGill University Senior Investigator, Lady Davis Institute for Medical Research, Jewish General Hospital</investigator_title>
  </responsible_party>
  <keyword>Scleroderma</keyword>
  <keyword>Systemic Sclerosis</keyword>
  <keyword>Support group</keyword>
  <keyword>Training</keyword>
  <keyword>Feasibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

